 NEW YORK, Nov. 1, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2021, including a corporate update, on Thursday, November 4, 2021, before market open. A webcast will follow at 8:00 am ET. 